BioSpace News Archive

Protagonist Therapeutics, Inc., a clinical stage biopharmaceutical company, announced the pricing of its previously announced underwritten public offering of 7,000,000 shares of its common stock at a price to the public of $14.00 per share.

Transparency Market Research has published a new report titled, “Surgical Robots Market”.

Transparency Market Research has published a new report titled, “neurorehabilitation devices market”.

According to the report, the medical device cleaning market was valued at ~US$ 2.8 Bn in 2018 and is expected to expand at a CAGR of ~5% during the forecast period.

International medical imaging IT and cybersecurity company Sectra will install the radiology and breast imaging modules of its enterprise imaging solution at Mayfair Diagnostics’ facilities in Canada.

- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following virtual investor conferences this month: BofA Securities 2020 Virtual Health Care Conference May 12-13 (presentation on May 12) Evercore ISI Vaccine Investor Day 2020 May 19 (no webcast presentation; virtual meetings only) 2020 6 th Annual SunTrust Robinson Humphrey Life Sciences Virt

ProMIS Neurosciences, Inc., a company with unique, core technology to predict novel targets on the molecular surface of complex proteins, has advanced its program to develop a high-throughput, highly accurate test for detection of antibodies to SARS CoV-2, the causative agent of COVID-19.

Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces the appointment of Diagnostic International Distribution S.p.A. of Milan (D.I.D.) as distributor of its Quality Assessment Products (QAPs™) for Italy. Under an agreement between the parties, D.I.D. has been appointed as distributor of Microbix’s quality assessment products (QAPs™) for Italy. As distributor, D.I.D. will provide

ROMAN Phase 3 Trial Topline Data Readout Guidance Updated to 2H21 Due to Impact of COVID-19 Amendment to Royalty Agreement for Additional $37.5M Extends Cash Runway into 2H22 Locally Advanced Pancreatic Cancer Phase 1b/2a Trial Topline Data Readout and Initiation of NSCLC Anti-cancer Phase 1b/2a Trial Both Remain On Track for 2H20 MALVERN, Pa., May 12, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a

IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 2020 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19 at 4:15 p.m. ET. The conference will be held in a virtual meeting format. A live webcast of the event will be available on the “Events and Prese